Treatment-related risk factors for inhibitor development
| Risk factor . | Relative risk . | 95% CI . |
|---|---|---|
| Age at first infusion < 6 months of age vs > 12 or 18 months | 1.828 | 0.7-4.7 |
| 1.727 | 1.3-1.9 | |
| Surgery at first infusion vs treatment of a bleed at first infusion > 5 days of treatment at first infusion vs < 2 days | 2.628 | 1.3-5.1 |
| 3.328 | 2.1-5.3 | |
| Prophylaxis vs no prophylaxis | 0.428 | 0.2-0.8 |
| 0.2*71 | 0.06-0.5 | |
| Plasma-derived product vs recombinant product | 2.427 | 1.0-5.8 |
| 0.832 | 0.5-1.3 |
| Risk factor . | Relative risk . | 95% CI . |
|---|---|---|
| Age at first infusion < 6 months of age vs > 12 or 18 months | 1.828 | 0.7-4.7 |
| 1.727 | 1.3-1.9 | |
| Surgery at first infusion vs treatment of a bleed at first infusion > 5 days of treatment at first infusion vs < 2 days | 2.628 | 1.3-5.1 |
| 3.328 | 2.1-5.3 | |
| Prophylaxis vs no prophylaxis | 0.428 | 0.2-0.8 |
| 0.2*71 | 0.06-0.5 | |
| Plasma-derived product vs recombinant product | 2.427 | 1.0-5.8 |
| 0.832 | 0.5-1.3 |
Odds ratio.